<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240815021350&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240815021350&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 15 Aug 2024 06:13:50 +0000</lastbuilddate>
<pubDate>Wed, 14 Aug 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Correction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39142734/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240815021350&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 20;84(8):771. doi: 10.1016/j.jacc.2024.07.009.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39142734/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240815021350&v=2.18.0.post9+e462414">39142734</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.009>10.1016/j.jacc.2024.07.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39142734</guid>
<pubDate>Wed, 14 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-14</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Correction</dc:title>
<dc:identifier>pmid:39142734</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.009</dc:identifier>
</item>
<item>
<title>Correction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39142733/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240815021350&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 20;84(8):771. doi: 10.1016/j.jacc.2024.07.010.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39142733/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240815021350&v=2.18.0.post9+e462414">39142733</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.010>10.1016/j.jacc.2024.07.010</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39142733</guid>
<pubDate>Wed, 14 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-14</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Correction</dc:title>
<dc:identifier>pmid:39142733</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.010</dc:identifier>
</item>
<item>
<title>Combined Surgical and Percutaneous Management of Circumflex Artery Occlusion After Minimally Invasive Mitral Valve Repair</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39142732/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240815021350&amp;v=2.18.0.post9+e462414
      <description>This report describes a hybrid intervention addressing left circumflex artery occlusion during minimally invasive mitral valve repair. By using a radiopaque Cor-Knot device (LSI Solutions), targeted removal of occluding sutures was achieved, circumventing sternotomy and coronary artery bypass. Real-time coronary angiography provided assessment of procedural success during surgical revision in a hybrid operating room.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 20;84(8):766-770. doi: 10.1016/j.jacc.2024.05.022.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">This report describes a hybrid intervention addressing left circumflex artery occlusion during minimally invasive mitral valve repair. By using a radiopaque Cor-Knot device (LSI Solutions), targeted removal of occluding sutures was achieved, circumventing sternotomy and coronary artery bypass. Real-time coronary angiography provided assessment of procedural success during surgical revision in a hybrid operating room.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39142732/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240815021350&v=2.18.0.post9+e462414">39142732</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.022>10.1016/j.jacc.2024.05.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39142732</guid>
<pubDate>Wed, 14 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Hristian Hinkov</dc:creator>
<dc:creator>Dustin Greve</dc:creator>
<dc:creator>Chong Bin Lee</dc:creator>
<dc:creator>Christoph Klein</dc:creator>
<dc:creator>Stephan Dreysse</dc:creator>
<dc:creator>Marian Kukucka</dc:creator>
<dc:creator>Serdar Akansel</dc:creator>
<dc:creator>Volkmar Falk</dc:creator>
<dc:creator>Markus Kofler</dc:creator>
<dc:creator>Jörg Kempfert</dc:creator>
<dc:date>2024-08-14</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Combined Surgical and Percutaneous Management of Circumflex Artery Occlusion After Minimally Invasive Mitral Valve Repair</dc:title>
<dc:identifier>pmid:39142732</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.022</dc:identifier>
</item>
<item>
<title>Cardiac Index in Comatose Survivors of Out-of-Hospital Cardiac Arrest</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39142731/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240815021350&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 20;84(8):764-765. doi: 10.1016/j.jacc.2024.05.054.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39142731/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240815021350&v=2.18.0.post9+e462414">39142731</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.054>10.1016/j.jacc.2024.05.054</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39142731</guid>
<pubDate>Wed, 14 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Juan J Russo</dc:creator>
<dc:creator>Paul Boland</dc:creator>
<dc:creator>Jordan Bernick</dc:creator>
<dc:creator>Pietro Di Santo</dc:creator>
<dc:creator>Derek Y F So</dc:creator>
<dc:creator>Benjamin Hibbert</dc:creator>
<dc:creator>Christopher B Fordyce</dc:creator>
<dc:creator>Sean van Diepen</dc:creator>
<dc:creator>Christian Hassager</dc:creator>
<dc:creator>Michel R Le May</dc:creator>
<dc:date>2024-08-14</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Cardiac Index in Comatose Survivors of Out-of-Hospital Cardiac Arrest</dc:title>
<dc:identifier>pmid:39142731</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.054</dc:identifier>
</item>
<item>
<title>Bridging the Gap: Tackling Global Challenges and Seizing Opportunities to Improve Access to CV Care</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39142730/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240815021350&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 20;84(8):761-763. doi: 10.1016/j.jacc.2024.07.005.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39142730/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240815021350&v=2.18.0.post9+e462414">39142730</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.005>10.1016/j.jacc.2024.07.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39142730</guid>
<pubDate>Wed, 14 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Cathleen Biga</dc:creator>
<dc:date>2024-08-14</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Bridging the Gap: Tackling Global Challenges and Seizing Opportunities to Improve Access to CV Care</dc:title>
<dc:identifier>pmid:39142730</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.005</dc:identifier>
</item>
<item>
<title>Optimizing Management of Stable Angina: A Patient-Centered Approach Integrating Revascularization, Medical Therapy, and Lifestyle Interventions</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39142729/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240815021350&amp;v=2.18.0.post9+e462414
      <description>Angina pectoris may arise from obstructive coronary artery disease (CAD) or in the absence of significant CAD (ischemia with nonobstructed coronary arteries [INOCA]). Therapeutic strategies for patients with angina and obstructive CAD focus on reducing cardiovascular events and relieving symptoms, whereas in INOCA the focus shifts toward managing functional alterations of the coronary circulation. In obstructive CAD, coronary revascularization might improve angina status, although a significant...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 20;84(8):744-760. doi: 10.1016/j.jacc.2024.06.015.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Angina pectoris may arise from obstructive coronary artery disease (CAD) or in the absence of significant CAD (ischemia with nonobstructed coronary arteries [INOCA]). Therapeutic strategies for patients with angina and obstructive CAD focus on reducing cardiovascular events and relieving symptoms, whereas in INOCA the focus shifts toward managing functional alterations of the coronary circulation. In obstructive CAD, coronary revascularization might improve angina status, although a significant percentage of patients present angina persistence or recurrence, suggesting the presence of functional mechanisms along with epicardial CAD. In patients with INOCA, performing a precise endotype diagnosis is crucial to allow a tailored therapy targeted toward the specific pathogenic mechanism. In this expert opinion paper, we review the evidence for the management of angina, highlighting the complementary role of coronary revascularization, optimal medical therapy, and lifestyle interventions and underscoring the importance of a personalized approach that targets the underlying pathobiology.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39142729/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240815021350&v=2.18.0.post9+e462414">39142729</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.015>10.1016/j.jacc.2024.06.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39142729</guid>
<pubDate>Wed, 14 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Rocco A Montone</dc:creator>
<dc:creator>Riccardo Rinaldi</dc:creator>
<dc:creator>Giampaolo Niccoli</dc:creator>
<dc:creator>Giuseppe Andò</dc:creator>
<dc:creator>Felice Gragnano</dc:creator>
<dc:creator>Raffaele Piccolo</dc:creator>
<dc:creator>Francesco Pelliccia</dc:creator>
<dc:creator>Elisabetta Moscarella</dc:creator>
<dc:creator>Marco Zimarino</dc:creator>
<dc:creator>Enrico Fabris</dc:creator>
<dc:creator>Salvatore de Rosa</dc:creator>
<dc:creator>Paolo Calabrò</dc:creator>
<dc:creator>Italo Porto</dc:creator>
<dc:creator>Francesco Burzotta</dc:creator>
<dc:creator>Francesco Grigioni</dc:creator>
<dc:creator>Emanuele Barbato</dc:creator>
<dc:creator>Alaide Chieffo</dc:creator>
<dc:creator>Davide Capodanno</dc:creator>
<dc:creator>Rasha Al-Lamee</dc:creator>
<dc:creator>Tom J Ford</dc:creator>
<dc:creator>Salvatore Brugaletta</dc:creator>
<dc:creator>Ciro Indolfi</dc:creator>
<dc:creator>Gianfranco Sinagra</dc:creator>
<dc:creator>Pasquale Perrone Filardi</dc:creator>
<dc:creator>Filippo Crea</dc:creator>
<dc:creator>Interventional Cardiology Working Group of the Italian Society of Cardiology</dc:creator>
<dc:date>2024-08-14</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Optimizing Management of Stable Angina: A Patient-Centered Approach Integrating Revascularization, Medical Therapy, and Lifestyle Interventions</dc:title>
<dc:identifier>pmid:39142729</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.015</dc:identifier>
</item>
<item>
<title>Point-of-Care High-Sensitivity Troponin Testing in the Emergency Department: The Way of the Future?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39142728/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240815021350&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 20;84(8):741-743. doi: 10.1016/j.jacc.2024.06.017.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39142728/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240815021350&v=2.18.0.post9+e462414">39142728</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.017>10.1016/j.jacc.2024.06.017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39142728</guid>
<pubDate>Wed, 14 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Aldo Clerico</dc:creator>
<dc:creator>Alberto Aimo</dc:creator>
<dc:creator>Claudio Passino</dc:creator>
<dc:date>2024-08-14</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Point-of-Care High-Sensitivity Troponin Testing in the Emergency Department: The Way of the Future?</dc:title>
<dc:identifier>pmid:39142728</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.017</dc:identifier>
</item>
<item>
<title>Clinical and Analytical Performance of a Novel Point-of-Care High-Sensitivity Cardiac Troponin I Assay</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39142727/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240815021350&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The SPINCHIP hs-cTnI POC test has very high diagnostic accuracy. Its assay-specific 0/1-hour algorithm achieved very high sensitivity/negative predictive value and specificity/positive predictive value for rule-out/in MI. (Advantageous Predictors of Acute Coronary Syndromes Evaluation [APACE] Study [APACE]; NCT00470587).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 20;84(8):726-740. doi: 10.1016/j.jacc.2024.05.056.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Point-of-care (POC) high-sensitivity cardiac troponin assays may further accelerate the diagnosis of myocardial infarction (MI).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to assess the clinical and analytical performance of the novel high-sensitivity cardiac troponin I (hs-cTnI)-SPINCHIP POC test.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Adult patients presenting with acute chest discomfort to the emergency department were enrolled in an international, diagnostic, multicenter study. The final diagnosis was centrally adjudicated by 2 independent cardiologists using all clinical information. We compared the discriminatory performance of hs-cTnI-SPINCHIP with current established central laboratory assays and derived an assay-specific hs-cTnI-SPINCHIP 0/1-hour algorithm. Secondary analyses included sample type comparisons (whole blood, fresh/frozen plasma, and capillary finger prick) and precision analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: MI was the adjudicated final diagnosis in 214 (19%) of 1,102 patients. Area under the receiver-operating characteristic curve was 0.94 (95% CI: 0.92-0.95) for hs-cTnI-SPINCHIP vs 0.94 (95% CI: 0.92-0.95) for hs-cTnI-Architect (P = 0.907) and 0.93 (95% CI: 0.91-0.95) for high-sensitivity cardiac troponin T Elecsys (P = 0.305). A cutoff &lt;7 ng/L at presentation (if chest pain onset was >;3 hours) or &lt;7 ng/L together with a 0/1-hour delta of &lt;4 ng/L ruled out 51% with a sensitivity and negative predictive value of 100% (95% CI: 97.7%-100%) and 100% (95% CI: 99.0%-100%), respectively. A hs-cTnI-SPINCHIP concentration ≥36 ng/L or a 0/1-hour delta ≥11 ng/L ruled in 27% with a specificity and positive predictive value of 90.9% (95% CI: 88.3%-92.9%) and 72.9% (95% CI: 66.4%-78.6%), respectively. Bootstrap internal validation confirmed excellent diagnostic performance. High agreement was observed between different sample types.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The SPINCHIP hs-cTnI POC test has very high diagnostic accuracy. Its assay-specific 0/1-hour algorithm achieved very high sensitivity/negative predictive value and specificity/positive predictive value for rule-out/in MI. (Advantageous Predictors of Acute Coronary Syndromes Evaluation [APACE] Study [APACE]; NCT00470587).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39142727/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240815021350&v=2.18.0.post9+e462414">39142727</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.056>10.1016/j.jacc.2024.05.056</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39142727</guid>
<pubDate>Wed, 14 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Luca Koechlin</dc:creator>
<dc:creator>Jasper Boeddinghaus</dc:creator>
<dc:creator>Pedro Lopez-Ayala</dc:creator>
<dc:creator>Cornelia Reber</dc:creator>
<dc:creator>Thomas Nestelberger</dc:creator>
<dc:creator>Karin Wildi</dc:creator>
<dc:creator>Carlos C Spagnuolo</dc:creator>
<dc:creator>Ivo Strebel</dc:creator>
<dc:creator>Jonas Glaeser</dc:creator>
<dc:creator>Paolo Bima</dc:creator>
<dc:creator>Luca Crisanti</dc:creator>
<dc:creator>Lourdes Herraiz-Recuenco</dc:creator>
<dc:creator>Elisa Dubach</dc:creator>
<dc:creator>Òscar Miró</dc:creator>
<dc:creator>F Javier Martin-Sanchez</dc:creator>
<dc:creator>Damian Kawecki</dc:creator>
<dc:creator>Dagmar I Keller</dc:creator>
<dc:creator>Michael Christ</dc:creator>
<dc:creator>Andreas Buser</dc:creator>
<dc:creator>Maria Rubini Giménez</dc:creator>
<dc:creator>Gro Leite Størvold</dc:creator>
<dc:creator>Marianne Nordlund Broughton</dc:creator>
<dc:creator>Torbjørn Omland</dc:creator>
<dc:creator>Magnus N Lyngbakken</dc:creator>
<dc:creator>Helge Røsjø</dc:creator>
<dc:creator>Christian Mueller</dc:creator>
<dc:creator>APACE Investigators</dc:creator>
<dc:date>2024-08-14</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Clinical and Analytical Performance of a Novel Point-of-Care High-Sensitivity Cardiac Troponin I Assay</dc:title>
<dc:identifier>pmid:39142727</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.056</dc:identifier>
</item>
<item>
<title>Acute Brain Infarctions and Periprocedural Stroke: Implications for Evaluating Cerebral Embolic Protection Devices</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39142726/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240815021350&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 20;84(8):723-725. doi: 10.1016/j.jacc.2024.06.018.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39142726/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240815021350&v=2.18.0.post9+e462414">39142726</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.018>10.1016/j.jacc.2024.06.018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39142726</guid>
<pubDate>Wed, 14 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Samir Kapadia</dc:creator>
<dc:creator>Amar Krishnaswamy</dc:creator>
<dc:creator>Michael Mack</dc:creator>
<dc:date>2024-08-14</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Acute Brain Infarctions and Periprocedural Stroke: Implications for Evaluating Cerebral Embolic Protection Devices</dc:title>
<dc:identifier>pmid:39142726</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.018</dc:identifier>
</item>
<item>
<title>Clinical Significance of Diffusion-Weighted Brain MRI Lesions After TAVR: Results of a Patient-Level Pooled Analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39142725/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240815021350&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our study confirms that the number, size, and total volume of acute brain infarction defined by DW-MRI are each associated with clinical ischemic strokes, disabling strokes, and worse stroke recovery in patients undergoing TAVR and may have value as surrogate outcomes in stroke prevention trials. (A Prospective, Randomized Evaluation of the TriGuard™ HDH Embolic Deflection Device During TAVI [DEFLECT III]; NCT02070731) (A Study to Evaluate the Neuro-embolic Consequences of TAVR...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 20;84(8):712-722. doi: 10.1016/j.jacc.2024.05.055.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Acute brain infarction detected by diffusion-weighted magnetic resonance imaging (DW-MRI) is common after transcatheter aortic valve replacement (TAVR), but its clinical relevance is uncertain.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The authors investigated the relationship between DW-MRI total lesion number (TLN), individual lesion volume (ILV), and total lesion volume (TLV) and clinical stroke outcomes after TAVR.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patient-level data were pooled from 4 prospective TAVR embolic protection studies, with consistent predischarge DW-MRI acquisition and core laboratory analysis. C-statistic was used to determine the best DW-MRI measure associated with clinical stroke.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 495 of 603 patients undergoing TAVR completed the predischarge DW-MRI. At 30 days, the rate of clinical ischemic stroke was 6.9%. Acute ischemic brain injury was seen in 85% of patients with 5.5 ± 7.3 discrete lesions per patient, mean ILV of 78.2 ± 257.1 mm<sup>3</sup>, and mean TLV of 555 ± 1,039 mm<sup>3</sup>. The C-statistic was 0.84 for TLV, 0.81 for number of lesions, and 0.82 for maximum ILV in predicting ischemic stroke. On the basis of the TLV cutpoint as defined by receiver operating characteristic (ROC), patients with a TLV >;500 mm<sup>3</sup> (vs TLV ≤500 mm<sup>3</sup>) had more ischemic stroke (18.2% vs 2.3%; P &lt; 0.0001), more disabling strokes (8.8% vs 0.9%; P &lt; 0.0001), and less complete stroke recovery (44% vs 62.5%; P = 0.001) at 30 days.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our study confirms that the number, size, and total volume of acute brain infarction defined by DW-MRI are each associated with clinical ischemic strokes, disabling strokes, and worse stroke recovery in patients undergoing TAVR and may have value as surrogate outcomes in stroke prevention trials. (A Prospective, Randomized Evaluation of the TriGuard™ HDH Embolic Deflection Device During TAVI [DEFLECT III]; NCT02070731) (A Study to Evaluate the Neuro-embolic Consequences of TAVR [NeuroTAVR]; NCT02073864) (The REFLECT Trial: Cerebral Protection to Reduce Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation [REFLECT I]; NCT02536196) (The REFLECT Trial: Cerebral Protection to Reduce Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation [REFLECT II]; NCT02536196).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39142725/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240815021350&v=2.18.0.post9+e462414">39142725</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.055>10.1016/j.jacc.2024.05.055</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39142725</guid>
<pubDate>Wed, 14 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Alexandra J Lansky</dc:creator>
<dc:creator>Daniel Grubman</dc:creator>
<dc:creator>Michael G Dwyer</dc:creator>
<dc:creator>Robert Zivadinov</dc:creator>
<dc:creator>Helen Parise</dc:creator>
<dc:creator>Jeffrey W Moses</dc:creator>
<dc:creator>Tayyab Shah</dc:creator>
<dc:creator>Cody Pietras</dc:creator>
<dc:creator>Daniela Tirziu</dc:creator>
<dc:creator>Louise Gambone</dc:creator>
<dc:creator>Martin B Leon</dc:creator>
<dc:creator>Tamim M Nazif</dc:creator>
<dc:creator>Steven R Messé</dc:creator>
<dc:date>2024-08-14</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Clinical Significance of Diffusion-Weighted Brain MRI Lesions After TAVR: Results of a Patient-Level Pooled Analysis</dc:title>
<dc:identifier>pmid:39142725</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.055</dc:identifier>
</item>
<item>
<title>Kidney and Cardiovascular Outcomes With SGLT2 Inhibitors and/or GLP-1 Receptor Agonists in Type 2 Diabetes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39142724/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240815021350&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 20;84(8):709-711. doi: 10.1016/j.jacc.2024.07.002.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39142724/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240815021350&v=2.18.0.post9+e462414">39142724</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.002>10.1016/j.jacc.2024.07.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39142724</guid>
<pubDate>Wed, 14 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Brendon L Neuen</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:date>2024-08-14</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Kidney and Cardiovascular Outcomes With SGLT2 Inhibitors and/or GLP-1 Receptor Agonists in Type 2 Diabetes</dc:title>
<dc:identifier>pmid:39142724</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.002</dc:identifier>
</item>
<item>
<title>Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39142723/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240815021350&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: SGLT2i and GLP-1 RAs led to similar kidney and cardiovascular outcomes in people with T2D, though SGLT2i initiation was associated with a lower risk of 40% eGFR decline. (Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease; NCT05465317).</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 20;84(8):696-708. doi: 10.1016/j.jacc.2024.06.016.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Emerging data suggest that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve kidney outcomes for people with type 2 diabetes (T2D). Direct comparisons of the kidney and cardiovascular effectiveness of GLP-1 RA with sodium-glucose cotransporter 2 inhibitors (SGLT2i), a first-line therapy for this population, are needed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The authors compared kidney and cardiovascular outcomes for new users of SGLT2i and GLP-1 RAs with T2D.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using propensity score overlap weighting, we analyzed electronic health record data from 20 U.S. health systems contributing to PCORnet between 2015 and 2020. The primary kidney outcome was a composite of sustained 40% estimated glomerular filtration rate (eGFR) decline, incident end-stage kidney disease, or all-cause mortality over 2 years or until censoring. In addition, we examined cardiovascular and safety outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The weighted study cohort included 35,004 SGLT2i and 47,268 GLP-1 RA initiators. Over a median of 1.2 years, the primary outcome did not differ between treatments (HR: 0.91; 95% CI: 0.81-1.02), although SGLT2i were associated with a lower risk of 40% eGFR decline (HR: 0.77; 95% CI: 0.65-0.91). Risks of mortality (HR: 1.08; 95% CI: 0.92-1.27), a composite of stroke, myocardial infarction, or death (HR: 1.03; 95% CI: 0.93-1.14), and heart failure hospitalization (HR: 0.95; 95% CI: 0.80-1.13) did not differ. Genital mycotic infections were more common for SGLT2i initiators, but other safety outcomes did not differ. The results were similar regardless of chronic kidney disease status.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: SGLT2i and GLP-1 RAs led to similar kidney and cardiovascular outcomes in people with T2D, though SGLT2i initiation was associated with a lower risk of 40% eGFR decline. (Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease; NCT05465317).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39142723/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240815021350&v=2.18.0.post9+e462414">39142723</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.016>10.1016/j.jacc.2024.06.016</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39142723</guid>
<pubDate>Wed, 14 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniel Edmonston</dc:creator>
<dc:creator>Hillary Mulder</dc:creator>
<dc:creator>Elizabeth Lydon</dc:creator>
<dc:creator>Karen Chiswell</dc:creator>
<dc:creator>Zachary Lampron</dc:creator>
<dc:creator>Christina Shay</dc:creator>
<dc:creator>Keith Marsolo</dc:creator>
<dc:creator>Raj C Shah</dc:creator>
<dc:creator>W Schuyler Jones</dc:creator>
<dc:creator>Howard Gordon</dc:creator>
<dc:creator>Wenke Hwang</dc:creator>
<dc:creator>Isabella Ayoub</dc:creator>
<dc:creator>Daniel Ford</dc:creator>
<dc:creator>Alanna Chamberlain</dc:creator>
<dc:creator>Ajaykumar Rao</dc:creator>
<dc:creator>Vivian Fonseca</dc:creator>
<dc:creator>Alexander Chang</dc:creator>
<dc:creator>Faraz Ahmad</dc:creator>
<dc:creator>Adriana Hung</dc:creator>
<dc:creator>Kelly Hunt</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Hayden B Bosworth</dc:creator>
<dc:creator>Neha Pagidipati</dc:creator>
<dc:date>2024-08-14</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes</dc:title>
<dc:identifier>pmid:39142723</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.016</dc:identifier>
</item>
<item>
<title>Cardiovascular Care in the United States: Penny Wise and Pound Foolish</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39142722/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240815021350&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 20;84(8):694-695. doi: 10.1016/j.jacc.2024.07.001.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39142722/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240815021350&v=2.18.0.post9+e462414">39142722</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.001>10.1016/j.jacc.2024.07.001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39142722</guid>
<pubDate>Wed, 14 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Tariq Ahmad</dc:creator>
<dc:creator>Nihar R Desai</dc:creator>
<dc:creator>Sara Tabtabai</dc:creator>
<dc:date>2024-08-14</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Cardiovascular Care in the United States: Penny Wise and Pound Foolish</dc:title>
<dc:identifier>pmid:39142722</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.001</dc:identifier>
</item>
<item>
<title>Prescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39142721/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240815021350&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In this analysis of U.S. data from 2022 to 2023, SGLT2 inhibitor prescription among people with a Class 1a recommendation is low. Interventions are needed to increase uptake of guideline-recommended SGLT2 inhibitor use.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 20;84(8):683-693. doi: 10.1016/j.jacc.2024.05.057.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce heart failure (HF) hospitalizations, recurrent cardiovascular events, and chronic kidney disease (CKD) progression, and thus constitute a Class 1a recommendation in people with diabetes and atherosclerotic cardiovascular disease, HF, or CKD and in people with severe albuminuria or HF, regardless of diabetes status.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to comprehensibly characterize the rate of SGLT2 inhibitor prescriptions among people with a Class 1a recommendation for SGLT2 inhibitor use.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Among 3,189,827 adults from 28 U.S. health systems within Optum Labs Data Warehouse between April 1, 2022, and March 31, 2023, we assessed SGLT2 inhibitor prescription rates, stratified by presence of diabetes and Class 1a recommendation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 716,387 adults with diabetes, 63.4% had a Class 1a recommendation for SGLT2 inhibitor therapy. There was little difference by Class 1a recommendation status (present: 11.9%; 95% CI: 11.9%-12.0% vs absent: 11.4%; 95% CI: 11.3%-11.6%; standardized mean difference: 1.3%). Among 2,473,440 adults without diabetes, 6.2% had a Class 1a recommendation for SGLT2 inhibitor therapy, and 3.1% (3.0%-3.2%) of those received a prescription. Internists/family practitioners initiated SGLT2 inhibitor prescriptions most commonly among people with diabetes, whereas specialists initiated SGLT2 inhibitor prescriptions most commonly among people without diabetes. No health system had >;25% SGLT2 inhibitor prescription rate among people with a Class 1a recommendation. Health systems with higher proportions of patients with commercial insurance and lower proportions with Medicare had higher SGLT2 inhibitor prescription rates.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this analysis of U.S. data from 2022 to 2023, SGLT2 inhibitor prescription among people with a Class 1a recommendation is low. Interventions are needed to increase uptake of guideline-recommended SGLT2 inhibitor use.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39142721/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240815021350&v=2.18.0.post9+e462414">39142721</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.057>10.1016/j.jacc.2024.05.057</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39142721</guid>
<pubDate>Wed, 14 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Jung-Im Shin</dc:creator>
<dc:creator>Yunwen Xu</dc:creator>
<dc:creator>Alexander R Chang</dc:creator>
<dc:creator>Juan J Carrero</dc:creator>
<dc:creator>Carina M Flaherty</dc:creator>
<dc:creator>Amrita Mukhopadhyay</dc:creator>
<dc:creator>Lesley A Inker</dc:creator>
<dc:creator>Saul B Blecker</dc:creator>
<dc:creator>Leora I Horwitz</dc:creator>
<dc:creator>Morgan E Grams</dc:creator>
<dc:date>2024-08-14</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Prescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems</dc:title>
<dc:identifier>pmid:39142721</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.057</dc:identifier>
</item>
<item>
<title>Schwann cell-secreted PGE&lt;sub>;2&lt;/sub>; promotes sensory neuron excitability during development</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39142281/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240815021350&amp;v=2.18.0.post9+e462414
      <description>Electrical excitability-the ability to fire and propagate action potentials-is a signature feature of neurons. How neurons become excitable during development and whether excitability is an intrinsic property of neurons remain unclear. Here, we demonstrate that Schwann cells, the most abundant glia in the peripheral nervous system, promote somatosensory neuron excitability during development. We find that Schwann cells secrete prostaglandin E(2), which is necessary and sufficient to induce...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Aug 6:S0092-8674(24)00827-4. doi: 10.1016/j.cell.2024.07.033. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Electrical excitability-the ability to fire and propagate action potentials-is a signature feature of neurons. How neurons become excitable during development and whether excitability is an intrinsic property of neurons remain unclear. Here, we demonstrate that Schwann cells, the most abundant glia in the peripheral nervous system, promote somatosensory neuron excitability during development. We find that Schwann cells secrete prostaglandin E<sub>2</sub>, which is necessary and sufficient to induce developing somatosensory neurons to express normal levels of genes required for neuronal function, including voltage-gated sodium channels, and to fire action potential trains. Inactivating this signaling pathway in Schwann cells impairs somatosensory neuron maturation, causing multimodal sensory defects that persist into adulthood. Collectively, our studies uncover a neurodevelopmental role for prostaglandin E<sub>2</sub> distinct from its established role in inflammation, revealing a cell non-autonomous mechanism by which glia regulate neuronal excitability to enable the development of normal sensory functions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39142281/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240815021350&v=2.18.0.post9+e462414">39142281</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.033>10.1016/j.cell.2024.07.033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39142281</guid>
<pubDate>Wed, 14 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Husniye Kantarci</dc:creator>
<dc:creator>Pablo D Elvira</dc:creator>
<dc:creator>Arun P Thottumkara</dc:creator>
<dc:creator>Emma M O'Connell</dc:creator>
<dc:creator>Manasi Iyer</dc:creator>
<dc:creator>Lauren J Donovan</dc:creator>
<dc:creator>Micaela Quinn Dugan</dc:creator>
<dc:creator>Nicholas Ambiel</dc:creator>
<dc:creator>Alejandro Granados</dc:creator>
<dc:creator>Hong Zeng</dc:creator>
<dc:creator>Nay L Saw</dc:creator>
<dc:creator>Amanda Brosius Lutz</dc:creator>
<dc:creator>Steven A Sloan</dc:creator>
<dc:creator>Erin E Gray</dc:creator>
<dc:creator>Khanh V Tran</dc:creator>
<dc:creator>Aditi Vichare</dc:creator>
<dc:creator>Ashley K Yeh</dc:creator>
<dc:creator>Alexandra E Münch</dc:creator>
<dc:creator>Max Huber</dc:creator>
<dc:creator>Aditi Agrawal</dc:creator>
<dc:creator>Maurizio Morri</dc:creator>
<dc:creator>Haining Zhong</dc:creator>
<dc:creator>Mehrdad Shamloo</dc:creator>
<dc:creator>Thomas Anthony Anderson</dc:creator>
<dc:creator>Vivianne L Tawfik</dc:creator>
<dc:creator>J Du Bois</dc:creator>
<dc:creator>J Bradley Zuchero</dc:creator>
<dc:date>2024-08-14</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Schwann cell-secreted PGE&lt;sub>;2&lt;/sub>; promotes sensory neuron excitability during development</dc:title>
<dc:identifier>pmid:39142281</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.033</dc:identifier>
</item>
<item>
<title>Epicardial and Pericardial Fat-Separated But Under the Same Roof-Reply</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39141398/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240815021350&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Aug 14. doi: 10.1001/jamacardio.2024.2427. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39141398/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240815021350&v=2.18.0.post9+e462414">39141398</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2427>10.1001/jamacardio.2024.2427</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39141398</guid>
<pubDate>Wed, 14 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Joel T Rämö</dc:creator>
<dc:creator>Patrick T Ellinor</dc:creator>
<dc:creator>James P Pirruccello</dc:creator>
<dc:date>2024-08-14</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Epicardial and Pericardial Fat-Separated But Under the Same Roof-Reply</dc:title>
<dc:identifier>pmid:39141398</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2427</dc:identifier>
</item>
<item>
<title>Routine Protamine Administration for Bleeding in Transcatheter Aortic Valve Implantation: The ACE-PROTAVI Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39141396/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240815021350&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In the ACE-PROTAVI randomized clinical trial, routine administration of protamine increased the rate of hemostasis success and decreased TTH. The beneficial effect of protamine was reflected in a reduction in minor vascular complications, procedural time, and postprocedural hospital stay duration in patients receiving routine protamine compared with patients receiving placebo.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Aug 14. doi: 10.1001/jamacardio.2024.2454. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Vascular complications after transfemoral transcatheter aortic valve implantation (TAVI) remain an important cause of procedure-related morbidity. Routine reversal of anticoagulation with protamine at the conclusion of transfemoral TAVI could reduce complications, but data remain scarce.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate the efficacy and safety of routine protamine administration after transfemoral TAVI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: The ACE-PROTAVI trial was an investigator-initiated, double-blind, placebo-controlled randomized clinical trial performed at 3 Australian hospitals between December 2021 and June 2023 with a 1-year follow-up period. All patients accepted for transfemoral TAVI by a multidisciplinary heart team were eligible for enrollment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Eligible patients were randomized 1:1 between routine protamine administration and placebo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The coprimary outcomes were the rate of hemostasis success and time to hemostasis (TTH), presented as categorical variables and compared with a χ2 test or as continuous variables as mean (SD) or median (IQR), depending on distribution. The major secondary outcome was a composite of all-cause death, major and minor bleeding complications, and major and minor vascular complications after 30 days, reported in odds ratios (ORs) with 95% CIs and P values.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study population consisted of 410 patients: 199 patients in the protamine group and 211 in the placebo group. The median (IQR) patient age in the protamine group was 82 (77-85) years, and 68 of 199 patients receiving protamine (34.2%) were female. The median (IQR) patient age in the placebo group was 80 (75-85) years, and 89 of 211 patients receiving the placebo (42.2%) were female. Patients receiving up-front protamine administration had a higher rate of hemostasis success (188 of 192 patients [97.9%]) than patients in the placebo group (186 of 203 patients [91.6%]; absolute risk difference, 6.3%; 95% CI, 2.0%-10.6%; P = .006); in addition, patients receiving up-front protamine had a shorter median (IQR) TTH (181 [120-420] seconds vs 279 [122-600] seconds; P = .002). Routine protamine administration resulted in a reduced risk of the composite outcome in the protamine group (10 of 192 [5.2%]) vs the placebo group (26 of 203 [12.8%]; OR, 0.37; 95% CI, 0.1-0.8; P = .01). This difference was predominantly driven by the difference in the prevalence of minor vascular complications. There were no adverse events associated with protamine use.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In the ACE-PROTAVI randomized clinical trial, routine administration of protamine increased the rate of hemostasis success and decreased TTH. The beneficial effect of protamine was reflected in a reduction in minor vascular complications, procedural time, and postprocedural hospital stay duration in patients receiving routine protamine compared with patients receiving placebo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12621001261808.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39141396/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240815021350&v=2.18.0.post9+e462414">39141396</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2454>10.1001/jamacardio.2024.2454</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39141396</guid>
<pubDate>Wed, 14 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Pieter A Vriesendorp</dc:creator>
<dc:creator>Shane Nanayakkara</dc:creator>
<dc:creator>Samuel Heuts</dc:creator>
<dc:creator>Jocasta Ball</dc:creator>
<dc:creator>Jaya Chandrasekar</dc:creator>
<dc:creator>Ronald Dick</dc:creator>
<dc:creator>Kawa Haji</dc:creator>
<dc:creator>Nay Min Htun</dc:creator>
<dc:creator>David McGaw</dc:creator>
<dc:creator>Samer Noaman</dc:creator>
<dc:creator>Sonny Palmer</dc:creator>
<dc:creator>Sesto Cairo</dc:creator>
<dc:creator>Mark Shulman</dc:creator>
<dc:creator>Enjarn Lin</dc:creator>
<dc:creator>Stuart Hastings</dc:creator>
<dc:creator>Benedict Waldron</dc:creator>
<dc:creator>George Proimos</dc:creator>
<dc:creator>Kean H Soon</dc:creator>
<dc:creator>Matias B Yudi</dc:creator>
<dc:creator>Adam Zimmet</dc:creator>
<dc:creator>Dion Stub</dc:creator>
<dc:creator>Antony S Walton</dc:creator>
<dc:date>2024-08-14</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Routine Protamine Administration for Bleeding in Transcatheter Aortic Valve Implantation: The ACE-PROTAVI Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39141396</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2454</dc:identifier>
</item>
<item>
<title>Verinurad Plus Allopurinol for Heart Failure With Preserved Ejection Fraction: The AMETHYST Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39141378/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240815021350&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Results of this randomized clinical trial show that despite substantial SUA lowering, verinurad plus allopurinol did not result in a significant improvement in peak VO2 or symptoms compared with allopurinol monotherapy or placebo in HFpEF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Aug 14. doi: 10.1001/jamacardio.2024.2435. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Elevated serum uric acid (SUA) level may contribute to endothelial dysfunction; therefore, SUA is an attractive target for heart failure with preserved ejection fraction (HFpEF). However, to the authors' knowledge, no prior randomized clinical trials have evaluated SUA lowering in HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To investigate the efficacy and safety of the novel urate transporter-1 inhibitor, verinurad, in patients with HFpEF and elevated SUA level.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was a phase 2, double-blind, randomized clinical trial (32-week duration) conducted from May 2020 to April 2022. The study took place at 59 centers in 12 countries and included patients 40 years and older with HFpEF and SUA level greater than 6 mg/dL. Data were analyzed from August 2022 to May 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Eligible patients were randomized 1:1:1 to once-daily, oral verinurad, 12 mg, plus allopurinol, 300 mg; allopurinol, 300 mg, monotherapy; or placebo for 24 weeks after an 8-week titration period. Allopurinol was combined with verinurad to prevent verinurad-induced urate nephropathy, and the allopurinol monotherapy group was included to account for allopurinol effects in the combination therapy group. All patients received oral colchicine, 0.5 to 0.6 mg, daily for the first 12 weeks after randomization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Key end points included changes from baseline to week 32 in peak oxygen uptake (VO2), Kansas City Cardiomyopathy Questionnaire total symptom score (KCCQ-TSS), and SUA level; and safety/tolerability (including adjudicated cardiovascular events).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 159 randomized patients (53 per treatment group; median [IQR] age, 71 [40-86] years; 103 male [65%]) with median (IQR) N-terminal pro-brain natriuretic peptide level of 527 (239-1044) pg/mL and SUA level of 7.5 (6.6-8.4) mg/dL, verinurad plus allopurinol (mean change, -59.6%; 95% CI, -64.4% to -54.2%) lowered SUA level to a greater extent than allopurinol (mean change, -37.6%; 95% CI, -45.3% to -28.9%) or placebo (mean change, 0.8%; 95% CI, -11.8% to 15.2%; P &lt; .001). Changes in peak VO2 (verinurad plus allopurinol, 0.27 mL/kg/min; 95% CI, -0.56 to 1.10 mL/kg/min; allopurinol, -0.17 mL/kg/min; 95% CI, -1.03 to 0.69 mL/kg/min; placebo, 0.37 mL/kg/min; 95% CI, -0.45 to 1.19 mL/kg/min) and KCCQ-TSS (verinurad plus allopurinol, 4.3; 95% CI, 0.3-8.3; allopurinol, 4.5; 95% CI, 0.3-8.6; placebo, 1.2; 95% CI, -3.0 to 5.3) were similar across groups. There were no adverse safety signals. Deaths or cardiovascular events occurred in 3 patients (5.7%) in the verinurad plus allopurinol group, 8 patients (15.1%) in the allopurinol monotherapy group, and 6 patients (11.3%) in the placebo group.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Results of this randomized clinical trial show that despite substantial SUA lowering, verinurad plus allopurinol did not result in a significant improvement in peak VO2 or symptoms compared with allopurinol monotherapy or placebo in HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04327024.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39141378/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240815021350&v=2.18.0.post9+e462414">39141378</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2435>10.1001/jamacardio.2024.2435</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39141378</guid>
<pubDate>Wed, 14 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Dalane W Kitzman</dc:creator>
<dc:creator>Adriaan A Voors</dc:creator>
<dc:creator>Robert J Mentz</dc:creator>
<dc:creator>Gregory D Lewis</dc:creator>
<dc:creator>Shira Perl</dc:creator>
<dc:creator>Robin Myte</dc:creator>
<dc:creator>Grace Kaguthi</dc:creator>
<dc:creator>C David Sjöström</dc:creator>
<dc:creator>Christian Källgren</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:date>2024-08-14</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Verinurad Plus Allopurinol for Heart Failure With Preserved Ejection Fraction: The AMETHYST Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39141378</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2435</dc:identifier>
</item>
<item>
<title>Epicardial and Pericardial Fat-Separated But Under the Same Roof</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39141368/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240815021350&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Aug 14. doi: 10.1001/jamacardio.2024.2424. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39141368/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240815021350&v=2.18.0.post9+e462414">39141368</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2424>10.1001/jamacardio.2024.2424</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39141368</guid>
<pubDate>Wed, 14 Aug 2024 06:00:00 -0400</pubDate>
<dc:creator>Gianluca Iacobellis</dc:creator>
<dc:date>2024-08-14</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Epicardial and Pericardial Fat-Separated But Under the Same Roof</dc:title>
<dc:identifier>pmid:39141368</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2424</dc:identifier>
</item>
<item>
<title>Error in Figure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39141066/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240815021350&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Aug 1;9(8):760. doi: 10.1001/jamacardio.2024.2323.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39141066/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240815021350&v=2.18.0.post9+e462414">39141066</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.2323>10.1001/jamacardio.2024.2323</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39141066</guid>
<pubDate>Wed, 14 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-14</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Error in Figure</dc:title>
<dc:identifier>pmid:39141066</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.2323</dc:identifier>
</item>
<item>
<title>JAMA Cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39141065/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240815021350&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Aug 1;9(8):678. doi: 10.1001/jamacardio.2023.3671.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39141065/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240815021350&v=2.18.0.post9+e462414">39141065</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3671>10.1001/jamacardio.2023.3671</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39141065</guid>
<pubDate>Wed, 14 Aug 2024 06:00:00 -0400</pubDate>
<dc:date>2024-08-14</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>JAMA Cardiology</dc:title>
<dc:identifier>pmid:39141065</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3671</dc:identifier>
</item>





























</channel>
</rss>